Vascarta Announces NIH Phase I clinical study of VAS-101 in sickle cell disease begins

Phase 1VAS-101Positive

AI Analysis

Summary

Vascarta announced the initiation of a second Phase 1 proof-of-concept clinical study investigating VAS-101 (topical curcumin gel) in patients with sickle cell disease, evaluating safety and tolerability of escalating doses.

Clinical Trial Data

Phase

Phase 1

Importance:5/10

Sentiment:

0.30

Phase 1 trialsickle cell diseaseVAS-101Vasceptorcurcumin gelNIH studysafety and tolerability

Read the original article

Published by PR Newswire Clinical Trials on August 19, 2026 6:18 PM

Read Original